Sutro Biopharma (STRO) Other financing activities (2017 - 2025)

Sutro Biopharma has disclosed Other financing activities across 9 years of filings, most recently posting $66000.0 for Q4 2025.

• Other financing activities for Q4 2025 came in at $66000.0, up 175.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $332000.0 (down 34.77% YoY), and the FY2025 annual result was $332000.0, down 34.77% from the prior year.
• Other financing activities came in at $66000.0 for Q4 2025 at Sutro Biopharma, up from $25000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $580000.0 in Q3 2021 to a low of -$135.7 million in Q4 2023.
• The 5-year median for Other financing activities is $61000.0 (2025), against an average of -$7.0 million.
• Across the five-year window, Other financing activities plunged 91.38% in 2022 and surged 516.67% in 2024, its largest moves.
• Sutro Biopharma's Other financing activities stood at -$84000.0 in 2021, then soared by 159.52% to $50000.0 in 2022, then plunged by 271536.0% to -$135.7 million in 2023, then soared by 100.02% to $24000.0 in 2024, then jumped by 175.0% to $66000.0 in 2025.
• The last three Other financing activities figures came in at $66000.0 (Q4 2025), $25000.0 (Q3 2025), and $61000.0 (Q2 2025), per Business Quant data.